ERBB2 and breast cancer: A phase 1b study explored the potential immune system activation benefits of combining atezolizumab and anti-HER2 therapies, including T-DM1, and observed increased PD-L1 levels and CD8 + T-cell infiltration in HER2+ BC [61].